CHAI is pleased to release the fifteenth issue of our annual HIV market report. The 2024 HIV Market Report provides a detailed look at the complex, ever-changing HIV landscape in low- and middle-income countries based on aggregated market intelligence.
Over the past decade, advances in HIV care have increased treatment coverage and reduced AIDS-related deaths. Many people living with HIV on treatment in low- and middle-income countries are now on an optimal, dolutegravir (DTG)-based regimen. But our work is not yet done.
- More than nine million people living with HIV are not on treatment, and many people cycle in and out of care, risking progressing to advanced HIV disease.
- Outcomes for children and adolescents living with HIV continue to lag far behind outcomes for adults.
- New infections remain stubbornly high at 1.3 million in 2023, and progress has been unequal across regions and population groups.
- Alongside improvements in life expectancy, increasing co-morbidities with non-communicable diseases present new health management challenges.
- Various political and economic contexts raise ever greater questions around future funding of and investment in essential HIV programs.
Transforming the HIV space
Despite these challenges, there is progress on the horizon. Groundbreaking updates in long-acting options for both treatment and prevention could transform the HIV space. These advancements offer person-centered and empowered choices. Integrating sexual and reproductive health services will improve access to treatment and prevention options. This includes expanded access for pregnant people. Development and wider use of HIV self-tests and multi-disease tests could help identify more cases, and link more individuals to care and prevention services. Momentum around integration of HIV services, including with primary health care, offers the opportunity to support client-centered, sustainable care.
Reinvigorated commitment is essential to sustain gains, close gaps, and scale-up transformational interventions. Continued momentum is needed to achieve and sustain HIV epidemic control – failure to do so risks significant setbacks.
